Abbott

As world leaders descended on the COP26 climate change conference in Glasgow this week, several pharma companies promoted their own ESG pledges.

First, Moderna on Monday outlined a commitment to achieve net-zero carbon emissions globally by 2030. The announcement touted a plan to use renewable or offset energy in all U.S. facilities starting this year and to implement sustainable construction for new plants in Africa and Canada. CEO Stéphane Bancel said in the press release that…

Thirteen leading pharma companies released third-quarter 2021 financial results in October, while one Japanese firm reported first-half 2021 results for the fiscal year ending in March. (Figures exclude exchange rate and portfolio changes where applicable.)

South Korea’s LG Chem saw its third-quarter numbers soar 70.7% over the same period last year, delivering $9.1 billion in sales. However, operating profit tumbled 20%, mainly due to a one-off expense associated with its electric…

Thirteen leading pharma companies released second-quarter 2021 financial results in July, while one Japanese firm reported first-quarter results for the fiscal year ending in March. (Figures exclude exchange rate and portfolio changes where applicable.)
 
Pfizer’s revenues soared 86% in the second quarter to $19 billion, beating consensus estimates of $17.5 billion. The Comirnaty Covid-19 vaccine led the results with $7.8 billion in sales. Based on contracts signed through mid-…

Twelve leading pharma companies released first-quarter 2021 financial results in April. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the round, Abbott’s first-quarter worldwide sales jumped 32.9% over last year’s to $10.5 billion, missing consensus estimates by 3.5%. Its diagnostics business continued to boom, with strong Covid-19 test sales driving 115% growth. The company said it has delivered nearly 700 million Covid-19 tests since the start of the…

Four leading pharma companies released fourth-quarter and full-year 2020 financial results in January. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the pack, Abbott’s fourth-quarter total sales soared 28.4% over last year to $10.7 billion—8% above consensus estimates. Diagnostics drove the surge: the company said it has delivered more than 400 million Covid-19 tests since the start of the pandemic, including more than 300 million tests in the fourth…

Mentions:

The state of the hunt:

Moderna’s became the second Covid-19 vaccine to receive U.S. FDA Emergency Use Authorization.
  COVAX has secured nearly 2 billion doses of vaccines but faces a “very high” failure risk, according to Reuters.
  Canada, Saudi Arabia and the United States have begun immunization campaigns using Pfizer/BioNTech’s jab.

 

Vaccines


Approved or authorized vaccines
 
The U.S. FDA granted Emergency Use Authorization (EUA…

Thirteen leading pharma companies released third-quarter 2020 financial results in October, and Japan’s Takeda (whose fiscal year ends in March) reported first-half numbers.

Leading the pack, bioMérieux’s quarterly sales soared 26.5% to $924 million, surpassing consensus estimates by 7%. The French diagnostics firm attributed the “exceptional momentum” to strong demand for its BioFire FilmArray testing solutions line and compatible Covid-19 tests. The company expects full-year sales…

The state of the hunt:

China will join the COVAX Facility, its foreign ministry announced Thursday.
  Regeneron requested U.S. FDA emergency authorization for a monoclonal antibody cocktail, and Eli Lilly planned a similar request for its mAb cocktail in November. 
  Remdesivir showed expanded benefits in final Phase 3 results published in the New England Journal of Medicine.

 

Vaccines

Phase 3 candidates:
 
The European Medicines Agency…

The state of the hunt:

Novavax brought its vaccine candidate to Phase 2.
  WHO reportedly offered wealthier countries new, more flexible terms for the COVAX Facility.
  The U.S. FDA expanded the Emergency Use Authorization for Gilead’s Veklury (remdesivir).

 

Vaccines

Phase 3 candidates:
 
Pfizer and BioNTech have enrolled more than half of the 30,000 people they seek for U.S.-based Phase 3 trials of their mRNA Covid-19 vaccine candidate,…

Twelve leading pharma companies released second-quarter 2020 financial results in July, and one Japanese firm (with a fiscal year ending in March) reported first-quarter numbers.

(Figures exclude exchange rate and portfolio changes where applicable.)

Leading the pack, AstraZeneca reported an 11% hike in total revenues to reach $6.3 billion in the quarter—slightly above consensus estimates. Amid the coronavirus lockdown, the British drugmaker saw strong product sales as its…